Integra LifeSciences (NASDAQ:IART) Stock Crosses Above 200 Day Moving Average – Here’s Why

Integra LifeSciences Holdings Corporation (NASDAQ:IART) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $14.35 and traded as high as $17.08. Integra LifeSciences shares last traded at $16.62, with a volume of 559,667 shares.

Analysts Set New Price Targets

Several research analysts have recently issued reports on IART shares. Wall Street Zen downgraded shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. UBS Group started coverage on Integra LifeSciences in a research report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 price objective on the stock. Citigroup reaffirmed a “neutral” rating and issued a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research report on Thursday, June 18th. Finally, Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $18.86.

Integra LifeSciences Trading Down 2.2%

The stock has a market cap of $1.28 billion, a P/E ratio of -182.65, a price-to-earnings-growth ratio of 0.85 and a beta of 1.21. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60. The firm’s fifty day simple moving average is $17.87 and its 200-day simple moving average is $14.40.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The company had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Equities research analysts expect that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

A number of large investors have recently bought and sold shares of IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Integra LifeSciences by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock valued at $889,000 after purchasing an additional 1,975 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Integra LifeSciences during the first quarter worth approximately $277,000. Goldman Sachs Group Inc. grew its stake in Integra LifeSciences by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock worth $36,515,000 after purchasing an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Integra LifeSciences by 23.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after purchasing an additional 45,693 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in Integra LifeSciences in the second quarter worth approximately $491,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.